Provectus Biopharmaceuticals, Inc. PVCT
0.05 USD 0.00 (+2.08%)
Nov 4, 2026, 10:02 AM EST
0.049 Day range 0.049
0.038 52-week range 0.077
- YTD
- -12.50%
- 1 year
- -28.99%
- Market cap
- 20.59M
- EPS (ttm)
- -0.01
- YTD return
- -12.50%
- 1-year return
- -28.99%
- Volume
- 40.86K
- Avg volume
- 109.34K
- Open
- 0.049
- Previous close
- 0.048
- Day's range
- 0.049 – 0.049
- 52-week range
- 0.038 – 0.077
1Y -0.0190 (-27.54%)
Financials — quick view
PVCT Revenue — quarterly 161.84K
PVCT Net income — quarterly -835.06K
PVCT EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
News
VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase 
Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose 
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections 
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium) 
Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript 
Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders 
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End 
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis 
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee 
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
Your note
Sign in to keep a note on PVCT — it syncs with the Stock Master app.